Medical Store Booked For Overpricing In Rewari

CHANDIGARH : A team of Food and Drug Administration on Sunday conducted a raid and seized medicines being sold at higher prices than MRP in Haryana’s Rewari district.

The raid was conducted on the instruction of the Haryana health and family welfare minister, Anil Vij.

Giving information in this regard, a spokesperson of the Food and Drug Administration said that acting on the tip-off, the Drug Control Officer, Rewari conducted a decoy operation at M/s Vinayak Medical Store where Sukhbir Singh, owner of the medical store was found selling cough syrup containing Codeine Phosphate at Rs 200 and capsule strip containing Tramadol Hydrochloride at Rs 100 without prescription by a registered pharmacist.

During the raid, Sukhbir could not produce the Retail Sale Drug License (RSDL) for the sale of these medicinal narcotic products, which he is selling at a higher price than the MRP. Notably, the MRP of the cough syrup is Rs 143 and the capsule strip is Rs 57.

The spokesman said that following the raid, 672 capsules containing tramadol and 7 syrups containing codeine phosphate were recovered. This medical store has been sealed and FIR against Sukhbir Singh and others under sections of NDPS Act and Essential Commodities Act 1955 and DPCO 2013 has been registered at police station, Kasola, Rewari.

He said that strict action will be taken against drug peddlers who indulged in such illicit practices.

  • Related Posts

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March